23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SYNDAX PHARMACEUTICALS INC. › 2023-2024

SYNDAX PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed May 15, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 218Asset managers, any item
  • 1,261Fund votes
  • May 15, 2024Meeting date

Results at a glance

Meeting of May 15, 2024: 5 items on SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed May 15, 2024: 5 passed (calculated).

Dissent

Significant dissent: 1 director (36.9% against).

Notable dissent: 1 director (13.1% against); 1 say-on-pay vote (73.9% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SYNDAX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SYNDAX PHARMACEUTICALS INC.

These tallies are SYNDAX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SYNDAX PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 15, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Martin H. Huber, M.D. 61,876,711---- 736,6253,032,770 99%Passed (calculated)—
Elect Director: Jennifer Jarrett 39,491,936---- 23,121,4003,032,770 63%Passed (calculated)—
Elect Director: William Meury 54,416,889---- 8,196,4473,032,770 87%Passed (calculated)—
2. Advisory vote on executive compensation 46,228,42116,304,79680,119 --3,032,770 74%Passed (calculated)—
3. Ratification of selection of independent registered public accounting firm 65,371,337253,27021,499 ---- 99.6%Passed (calculated)—

Source: SYNDAX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 15, 2024 — read the filing on EDGAR.

How asset managers voted at the SYNDAX PHARMACEUTICALS INC. 2023-2024 meeting

218 asset managers disclosed a vote on at least one SYNDAX PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jennifer Jarrett

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%WITHHELD
FOR: 39,491,936WITHHELD: 23,121,400
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Jennifer Jarrett

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Jarrett”): 39,491,936 for, 23,121,400 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 16,535,343 for, 8,286,958 withheld.

FORWITHHOLD
FOR: 16,535,343WITHHOLD: 8,286,958
Largest asset managers voting on “Election of Directors: Jennifer Jarrett” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,905,2460 00For
BlackRock3,561,8110 00For
State Street3,1330 03,196,274Withhold
Fidelity1,771,6140 00For
T. Rowe Price14,5870 01,353,833Withhold
FRANKLIN STRATEGIC SERIES761,4510 00For
Charles Schwab00 0634,277Withhold
Columbia Threadneedle00 0470,690Withhold
Hartford450,1880 00For
JPMorgan00 0409,750Withhold
TIAA00 0390,922Withhold
Federated Hermes354,6640 00For
Direxion Shares ETF Trust00 0219,075Withhold
Equitable121,1990 076,160Mixed
John Hancock96,1140 093,926Mixed
Delaware/Macquarie00 0180,000Withhold
QUANTITATIVE MASTER SERIES LLC138,1020 00For
Exchange Place Advisors Trust00 0137,480Withhold
Brighthouse33,0270 074,650Mixed
Dimensional00 0103,530Withhold
AIG/SunAmerica00 0102,073Withhold
Prudential/PGIM56,4520 039,202Mixed
Allspring00 094,139Withhold
Victory Capital1,6530 077,970Withhold
Lincoln Financial00 075,145Withhold

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Elect Director: Martin H. Huber, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 61,876,711WITHHELD: 736,625
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: Martin H. Huber, M.D.

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martin H. Huber, M.D.”): 61,876,711 for, 736,625 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 24,585,931 for, 236,370 withheld.

FOR
FOR: 24,585,931WITHHOLD: 236,370
Largest asset managers voting on “Election of Directors: Martin H. Huber, M.D.” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,905,2460 00For
BlackRock3,561,8110 00For
State Street3,199,0270 0380For
Fidelity1,740,9120 030,702For
T. Rowe Price1,368,4200 00For
FRANKLIN STRATEGIC SERIES761,4510 00For
Charles Schwab634,2770 00For
Columbia Threadneedle470,6900 00For
Hartford450,1880 00For
JPMorgan409,7500 00For
TIAA390,9220 00For
Federated Hermes354,6640 00For
Direxion Shares ETF Trust219,0750 00For
Equitable121,1990 076,160Mixed
John Hancock190,0400 00For
Delaware/Macquarie180,0000 00For
QUANTITATIVE MASTER SERIES LLC138,1020 00For
Exchange Place Advisors Trust137,4800 00For
Brighthouse107,6770 00For
Dimensional00 0103,530Withhold
AIG/SunAmerica102,0730 00For
Prudential/PGIM95,6540 00For
Allspring94,1390 00For
Victory Capital79,6230 00For
Lincoln Financial75,1450 00For

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Elect Director: William Meury

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 54,416,889WITHHELD: 8,196,447
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Election of Directors: William Meury

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Meury”): 54,416,889 for, 8,196,447 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 20,578,485 for, 4,243,816 withheld.

FORWITHHOLD
FOR: 20,578,485WITHHOLD: 4,243,816
Largest asset managers voting on “Election of Directors: William Meury” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,905,2460 00For
BlackRock00 03,561,811Withhold
State Street3,199,0270 0380For
Fidelity1,691,3520 080,262For
T. Rowe Price1,368,4200 00For
FRANKLIN STRATEGIC SERIES761,4510 00For
Charles Schwab634,2770 00For
Columbia Threadneedle470,6900 00For
Hartford450,1880 00For
JPMorgan409,7500 00For
TIAA390,9220 00For
Federated Hermes354,6640 00For
Direxion Shares ETF Trust219,0750 00For
Equitable00 0197,359Withhold
John Hancock190,0400 00For
Delaware/Macquarie180,0000 00For
QUANTITATIVE MASTER SERIES LLC00 0138,102Withhold
Exchange Place Advisors Trust137,4800 00For
Brighthouse107,6770 00For
Dimensional00 0103,530Withhold
AIG/SunAmerica102,0730 00For
Prudential/PGIM95,6540 00For
Allspring94,1390 00For
Victory Capital79,6230 00For
Lincoln Financial75,1450 00For

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Advisory vote on executive compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST
FOR: 46,228,421AGAINST: 16,304,796
Details: description as filed, official tally, votes by 215 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE 2024 PROXY STATEMENT.

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory vote on executive compensation”): 46,228,421 for, 16,304,796 against, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 70 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,655,8944,249,352 00Mixed
BlackRock3,561,8110 00For
State Street3,199,4070 00For
Fidelity1,771,6140 00For
T. Rowe Price1,368,4200 00For
FRANKLIN STRATEGIC SERIES761,4510 00For
Charles Schwab0634,277 00Against
Columbia Threadneedle470,6900 00For
Hartford0450,188 00Against
JPMorgan409,7500 00For
TIAA390,9220 00For
Federated Hermes354,6640 00For
Direxion Shares ETF Trust219,0750 00For
Equitable197,3590 00For
John Hancock93,92696,114 00Mixed
Delaware/Macquarie180,0000 00For
QUANTITATIVE MASTER SERIES LLC138,1020 00For
Exchange Place Advisors Trust0137,480 00Against
Brighthouse74,65033,027 00Mixed
Dimensional0103,530 00Against
AIG/SunAmerica102,0730 00For
Prudential/PGIM39,20256,452 00Mixed
Allspring94,1390 00For
Victory Capital77,9701,653 00For
Simplify Exchange Traded Funds25,6250 050,000Mixed

Fund voting reports, all 70 managers: 18,901,000 for, 5,929,186 against, 50,000 withheld, 17,740 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 168 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Wellington07,027,115 00Against
Kynam Capital Management, LP00 05,660,000Withhold
State Street4,702,9650 00For
Eversept Partners, LP3,225,9970 00For
BlackRock3,060,7130 00For
T. Rowe Price2,404,5910 00For
MARSHALL WACE, LLP02,048,017 00Against
BVF INC/IL1,875,0000 00For
GEODE CAPITAL MANAGEMENT, LLC1,781,6070 00For
Avidity Partners Management LP01,752,627 00Against
ORBIMED ADVISORS LLC01,749,000 00Against
FRANKLIN ADVISERS INC1,394,5140 00For
Aisling Capital Management LP1,025,0000 00For
Candriam S.C.A.999,9340 00For
Sofinnova Investments, Inc.930,2870 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.900,0000 00For
KINGDON CAPITAL MANAGEMENT, L.L.C.0887,094 00Against
Foresite Capital Management IV, LLC875,0000 00For
JPMorgan696,6230 00For
Northern Trust668,69144 00For
DAFNA Capital Management LLC665,5740 00For
PFM Health Sciences, LP658,6940 00For
Charles Schwab0634,381 00Against
Palo Alto Investors LP472,6000 00For
Avoro Capital Advisors LLC437,7160 00For

Institutional-manager reports, all 168 managers: 32,538,950 for, 15,673,792 against, 5,660,000 withheld, 1,394 abstained, 175 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of selection of independent registered public accounting firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 65,371,337AGAINST: 253,270
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 65,371,337 for, 253,270 against, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the shares present or represented, the standard stated in the company’s proxy statement: votes for exceeded votes against plus abstentions.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 24,803,846 for, 715 against, 17,740 abstained.

FOR
FOR: 24,803,846AGAINST: 715ABSTAIN: 17,740
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE C” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,905,2460 00For
BlackRock3,561,8110 00For
State Street3,198,901506 00For
Fidelity1,771,6140 00For
T. Rowe Price1,368,4200 00For
FRANKLIN STRATEGIC SERIES761,4510 00For
Charles Schwab634,2770 00For
Columbia Threadneedle470,6900 00For
Hartford450,1880 00For
JPMorgan409,7500 00For
TIAA390,9220 00For
Federated Hermes354,6640 00For
Direxion Shares ETF Trust219,0750 00For
Equitable197,3590 00For
John Hancock190,0400 00For
Delaware/Macquarie180,0000 00For
QUANTITATIVE MASTER SERIES LLC138,1020 00For
Exchange Place Advisors Trust137,4800 00For
Brighthouse107,6770 00For
Dimensional103,5300 00For
AIG/SunAmerica102,0730 00For
Prudential/PGIM95,6540 00For
Allspring94,1390 00For
Victory Capital79,6230 00For
Lincoln Financial75,1450 00For

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Largest SYNDAX PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,979,686 shares outstanding at the time of that meeting.

Fund voting reports: top SYNDAX PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 10.48%
2BlackRock 4.19%
3State Street 3.76%
4Fidelity 2.08%
5T. Rowe Price 1.61%
6FRANKLIN STRATEGIC SERIES 0.90%
7Charles Schwab 0.75%
8Columbia Threadneedle 0.55%
9Hartford 0.53%
10JPMorgan 0.48%
Institutional-manager reports: top SYNDAX PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2023-2024
#Asset manager % of shares outstanding
1Wellington 8.27%
2Kynam Capital Management, LP 6.66%
3State Street 5.53%
4Eversept Partners, LP 3.80%
5BlackRock 3.60%
6T. Rowe Price 2.83%
7MARSHALL WACE, LLP 2.41%
8BVF INC/IL 2.21%
9GEODE CAPITAL MANAGEMENT, LLC 2.10%
10Avidity Partners Management LP 2.06%

Reported SYNDAX PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SYNDAX PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock8,625,244 10.15%Form 13F, quarter ended March 31, 2024
Entities affiliated with Wellington Group, LLP.7,585,221 8.93%Proxy statement (DEF 14A), proxy filed April 2, 2024
Wellington Management7,436,616 8.75%Form 13F, quarter ended March 31, 2024
Entities affiliated with BlackRock, Inc.7,015,548 8.26%Proxy statement (DEF 14A), proxy filed April 2, 2024
Entities affiliated with Kynam Capital Management, LP5,660,000 6.66%Proxy statement (DEF 14A), proxy filed April 2, 2024
Goldman Sachs5,486,434 6.46%Form 13F, quarter ended March 31, 2024
Vanguard Group5,138,617 6.05%Form 13F, quarter ended March 31, 2024
State Street4,819,594 5.67%Form 13F, quarter ended March 31, 2024
S3,950,000 4.65%Schedule 13G, filed February 13, 2024
Point722,066,685 2.43%Form 13F, quarter ended March 31, 2024

Percentages above are of 84,979,686 shares outstanding, as reported by SYNDAX PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SYNDAX PHARMACEUTICALS INC.'s shareholder meeting held May 15, 2024, in the 2023-2024 proxy season, 218 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,261 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SYNDAX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SYNDAX PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SYNDAX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “SYNDAX PHARMACEUTICALS (SNDX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/syndax-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.